Suppression of polyclonal immunoglobulins in multiple myeloma: Relationship to the staging and other manifestations at diagnosis
作者： W. Pruzanski , Martie S. Gidon , Ann Roy
DOI: 10.1016/0090-1229(80)90097-5
关键词: Stage ii 、 Medicine 、 Stage (cooking) 、 Pathology 、 Polyclonal antibodies 、 Antibody 、 Multiple myeloma
摘要: Abstract Nine hundred and forty patients with multiple myeloma were analyzed at diagnosis for the prevalence of suppressed polyclonal immunoglobulins in relation to various laboratory data. Of 940 patients, 689 staged diagnosis: 185 (27%) stage I, 297 (43%) II, 207 (30%) III. In total group all 75%, one normal immunoglobulin was found 16% two or three 9%. There a highly significant relationship (P
elsevier.com
sci-hub.se 参考文章(17)
Paul P. Carbone, Leland E. Kellerhouse, Edmund A. Gehan, Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. The American Journal of Medicine. ,vol. 42, pp. 937- 948 ,(1967) , 10.1016/0002-9343(67)90074-5
C Shustik, DE Bergsagel, W Pruzanski, Kappa and lambda light chain disease: survival rates and clinical manifestations Blood. ,vol. 48, pp. 41- 51 ,(1976) , 10.1182/BLOOD.V48.1.41.BLOODJOURNAL48141
Robert A Kyle, Monoclonal gammopathy of undetermined significance The American Journal of Medicine. ,vol. 64, pp. 814- 826 ,(1978) , 10.1016/0002-9343(78)90522-3
Samuel Broder, Richard Humphrey, Mary Durm, Marcia Blackman, Bruce Meade, Carolyn Goldman, Warren Strober, Thomas Waldmann, Impaired Synthesis of Polyclonal (Non-Paraprotein) Immunoglobulins by Circulating Lymphocytes from Patients with Multiple Myeloma New England Journal of Medicine. ,vol. 293, pp. 887- 892 ,(1975) , 10.1056/NEJM197510302931801
Folke D. Lindström, Ulf Dahlström, Multiple myeloma or benign monoclonal gammopathy? A study of differential diagnostic criteria in 44 cases Clinical Immunology and Immunopathology. ,vol. 10, pp. 168- 174 ,(1978) , 10.1016/0090-1229(78)90024-7
Paul Heller, The mechanism of the immunologic deficiency in myeloma of man and mouse Annals of Hematology. ,vol. 37, pp. 65- 68 ,(1978) , 10.1007/BF01002103
Zygmunt Jancelewicz, IgD Multiple Myeloma Archives of Internal Medicine. ,vol. 135, pp. 87- 93 ,(1975) , 10.1001/ARCHINTE.1975.00330010089012
Brian G. M. Durie, Sydney E. Salmon, A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer. ,vol. 36, pp. 842- 854 ,(1975) , 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
Soila Peltonen, Curt Wasastjerna, Odd Wager, Clinical features of patients with a serum M component. Acta Medica Scandinavica. ,vol. 203, pp. 257- 263 ,(2009) , 10.1111/J.0954-6820.1978.TB14869.X
FOLKE D. LINDSTRÖM, Multiple Myeloma and Benign Monoclonal Gammopathy: Differentiation by Immunofluorescence of Lymphocytes Annals of Internal Medicine. ,vol. 78, pp. 837- 844 ,(1973) , 10.7326/0003-4819-78-6-837